Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Next-generation prognostic assessment for diffuse large B-cell lymphomaGene expression analysis in RA: towards personalized medicineTreatment of diffuse large B cell lymphomaInterim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent updateA microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphomaUtility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma.Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives.MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategiesEvaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithmsImmunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.The histological classification of diffuse large B-cell lymphomasAggressive B-cell lymphomas: how many categories do we need?Identification and validation of a two-gene expression index for subtype classification and prognosis in Diffuse Large B-Cell LymphomaThe expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphomaMultiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphomaA Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.Genetic lesions in diffuse large B-cell lymphomasPrognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue BiopsiesFrontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphomaMachine Learning-based Classification of Diffuse Large B-cell Lymphoma Patients by Their Protein Expression Profiles.Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classificationPrognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.Molecular profiling reveals prognostically significant subtypes of canine lymphoma.Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions.The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP ConCD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium PrPrimary diffuse large B-cell lymphoma of the ascending colon.
P2860
Q24597424-A13E4715-3068-4482-99E2-1D8D70DC7AE2Q26796428-82CA7B19-D893-46E9-A9F6-97A51406DCA7Q26825706-965CA1C7-D2AB-4DB4-A472-C49EC544414CQ27006062-DA313F2D-4FE0-4EE1-9169-42EC69D9DFD8Q27314782-EF0767C6-5EAD-4DAB-A391-C9043FE8C3ADQ27314809-185B1964-A865-485A-80C0-B9756CAA20B4Q28078869-B3AB032D-2EB1-4D1E-8D2A-814F9B65DE6EQ30485971-6114D997-B542-42AA-B81F-51BFFDF4004EQ33435420-3A560098-8117-4CE6-ADCC-2D16169E39D2Q33591789-37E8AF82-ACE8-4C8E-B46C-D2DD789837D2Q33700531-97AF072F-D3FF-40A7-83EB-7B8D69A358B0Q33729711-5FF2CC96-2B9E-46C3-BE5F-F316377DC3D9Q34000188-4DEE05D8-0FCE-47F4-BC0E-46B66E9FB617Q34292361-4750B88E-5714-4A7E-B4DA-943C1B9FECD3Q34390837-57553E77-B9D8-4899-97C2-49245A5F469DQ34617849-4BF6CC86-3440-4FCB-9B3E-CA01A6D50F6BQ35193836-13C6F089-8B3F-4EF4-848E-E492FD0A55E2Q35218051-EE8F8B8D-403F-4876-B18B-7CF58B94A5FAQ35527893-595EEFC4-10D1-4507-9145-5698A9B2AACEQ35569017-4BCD4690-4D78-4F01-85DF-2D992BFD5ED6Q35606714-299B24EA-31E4-4C23-936A-0F96852CB584Q35755485-A56BAA6D-5A34-45CD-97B7-D4F3DBFC41D4Q35797583-A52D0E1F-541C-473D-884B-F8FBA90E76DEQ35930640-B156405E-E77B-4C84-AAF2-6CD1A76DDA84Q35974341-3C5CBBE7-96A7-4FDB-8659-58DD5708AC6EQ36011142-DC9E1415-2FAF-4583-B49B-F7ADDE338392Q36192439-D3B33962-6EDF-432B-9598-5DFB8CA466BAQ36249448-EA26A3E9-0422-42E9-9003-5D53260B5901Q36263022-67034F1B-1906-488C-ACC7-392807EE30E2Q36267666-0F22FF8A-B69C-4673-A2C0-F81E695F0556Q36280547-7B7290D4-DE6E-456E-BF19-294C1E1DA9ABQ36317453-4DD9FE16-5522-4F79-8391-BCBF276239B2Q36381346-2FA6EFEB-FA6D-4D79-871B-9AA0DD46994FQ36474669-DDE9E602-3838-4D8B-8E81-FFD2A87F093CQ36559885-11627FEA-D5E2-4869-909B-FB62FC8B0EDCQ36776444-93A2CA7F-1AD5-4F04-AC51-1D956AD76C74Q36799606-8F1095E5-5793-4972-A15D-042698DD4E5FQ36979534-FD6D29F5-38B0-44A6-BD0A-B0786E4B7302Q37006876-9655F961-92DF-4971-BBAA-9AB0A989E2A1Q37034634-952FA295-4AA8-4C74-9958-64854356C932
P2860
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Gene-expression profiling and ...... reated with immunochemotherapy
@ast
Gene-expression profiling and ...... reated with immunochemotherapy
@en
Gene-expression profiling and ...... reated with immunochemotherapy
@nl
type
label
Gene-expression profiling and ...... reated with immunochemotherapy
@ast
Gene-expression profiling and ...... reated with immunochemotherapy
@en
Gene-expression profiling and ...... reated with immunochemotherapy
@nl
prefLabel
Gene-expression profiling and ...... reated with immunochemotherapy
@ast
Gene-expression profiling and ...... reated with immunochemotherapy
@en
Gene-expression profiling and ...... reated with immunochemotherapy
@nl
P2093
P50
P3181
P1433
P1476
Gene-expression profiling and ...... reated with immunochemotherapy
@en
P2093
Adriana García-Herrera
Alejandra Martínez-Trillos
Alexandra Valera
Antonio Martínez
Armando López-Guillermo
Fina Climent
Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB)
José L Mate
Juan M Sancho
P304
P3181
P356
10.1182/BLOOD-2010-12-322362
P407
P577
2011-03-25T00:00:00Z